Last reviewed · How we verify

HLX10, an engineered anti-PD-1 antibody

Shanghai Henlius Biotech · Phase 3 active Small molecule

HLX10, an engineered anti-PD-1 antibody is a PD-1 inhibitor Small molecule drug developed by Shanghai Henlius Biotech. It is currently in Phase 3 development for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).

HLX10 is an engineered anti-PD-1 monoclonal antibody that blocks the PD-1 checkpoint on T cells, allowing them to recognize and attack cancer cells.

HLX10 is an engineered anti-PD-1 monoclonal antibody that blocks the PD-1 checkpoint on T cells, allowing them to recognize and attack cancer cells. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).

At a glance

Generic nameHLX10, an engineered anti-PD-1 antibody
SponsorShanghai Henlius Biotech
Drug classPD-1 inhibitor
TargetPD-1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

PD-1 is an immune checkpoint receptor that cancer cells exploit to suppress T cell activity. By binding to PD-1, HLX10 prevents the interaction between PD-1 and its ligands (PD-L1/PD-L2), thereby releasing the brake on anti-tumor immunity. This engineered antibody is designed to enhance immune activation against malignant cells while potentially optimizing safety and efficacy profiles.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about HLX10, an engineered anti-PD-1 antibody

What is HLX10, an engineered anti-PD-1 antibody?

HLX10, an engineered anti-PD-1 antibody is a PD-1 inhibitor drug developed by Shanghai Henlius Biotech, indicated for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).

How does HLX10, an engineered anti-PD-1 antibody work?

HLX10 is an engineered anti-PD-1 monoclonal antibody that blocks the PD-1 checkpoint on T cells, allowing them to recognize and attack cancer cells.

What is HLX10, an engineered anti-PD-1 antibody used for?

HLX10, an engineered anti-PD-1 antibody is indicated for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).

Who makes HLX10, an engineered anti-PD-1 antibody?

HLX10, an engineered anti-PD-1 antibody is developed by Shanghai Henlius Biotech (see full Shanghai Henlius Biotech pipeline at /company/shanghai-henlius-biotech).

What drug class is HLX10, an engineered anti-PD-1 antibody in?

HLX10, an engineered anti-PD-1 antibody belongs to the PD-1 inhibitor class. See all PD-1 inhibitor drugs at /class/pd-1-inhibitor.

What development phase is HLX10, an engineered anti-PD-1 antibody in?

HLX10, an engineered anti-PD-1 antibody is in Phase 3.

What are the side effects of HLX10, an engineered anti-PD-1 antibody?

Common side effects of HLX10, an engineered anti-PD-1 antibody include Fatigue, Decreased appetite, Nausea, Immune-related adverse events (irAEs), Pneumonitis, Hepatotoxicity.

What does HLX10, an engineered anti-PD-1 antibody target?

HLX10, an engineered anti-PD-1 antibody targets PD-1 and is a PD-1 inhibitor.

Related